Fludarabine phosphate

Highest phase reached

Approved

www.ebi.ac.uk

Drug type

Small molecule

www.ebi.ac.uk

First approval year

1991

www.ebi.ac.uk

First approval year: 1991
www.ebi.ac.uk

Listing at source: Listed

Highest phase reached: Approved
www.ebi.ac.uk

Drug type: Small molecule
www.ebi.ac.uk

Drug name: Fludarabine phosphate
www.ebi.ac.uk

Molecular weight: 365.21
www.ebi.ac.uk

Structure (SMILES): Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
www.ebi.ac.uk

fludara
Fludara
fludarabine phosphate
Fludarabine phosphate
oforta
Oforta

2 f ara amp
2-f-ara-amp
9 beta d arabinofuranosyl 2 fluoroadenine 5 dihydrogen phosphate
9-.BETA.-D-ARABINOFURANOSYL-2-FLUOROADENINE 5'-(DIHYDROGEN PHOSPHATE)
9h purin 6 amine 2 fluoro 9 5 o phosphono beta d arabinofuranosyl
9H-PURIN-6-AMINE, 2-FLUORO-9-(5-O-PHOSPHONO-.BETA.-D-ARABINOFURANOSYL)-
fludara
Fludara
fludarabine 5 monophosphate
fludarabine 5 monophosphate mi
Fludarabine 5'-monophosphate
FLUDARABINE 5'-MONOPHOSPHATE [MI]
fludarabine monophosphate
Fludarabine monophosphate
fludarabine phosphate
Fludarabine phosphate
FLUDARABINE PHOSPHATE [EP MONOGRAPH]
FLUDARABINE PHOSPHATE [JAN]
FLUDARABINE PHOSPHATE [MART.]
FLUDARABINE PHOSPHATE [ORANGE BOOK]
FLUDARABINE PHOSPHATE [USAN]
FLUDARABINE PHOSPHATE [USP MONOGRAPH]
FLUDARABINE PHOSPHATE [USP-RS]
FLUDARABINE PHOSPHATE [VANDF]
Fludarabine phosphate [WHO-DD]

And 13 more, listed on the interactive page.

ATC classification codes

L01BB05

Sources for recorded values

www.ebi.ac.uk

CAS registry numbers

75607-67-9

ChEMBL ID: CHEMBL1096882
www.ebi.ac.uk

InChIKey: GIUYCYHIANZCFB-FJFJXFQQSA-N
www.ebi.ac.uk

PubChem compound IDs

30751

FDA ingredient codes (UNII)

1X9VK9O1SC

24698
25102

Applicant: SAGENT PHARMS INC
Approval date: 28 Apr 2004
Application number: ANDA076661

Patents: 0
Designations: 3
First in class: No
Fast track: No
Breakthrough designation: No
Orphan designation: No
Priority review: Yes
Orphan exclusivity: No
Accelerated approval: No
Availability: Prescription only
Boxed warning: Yes

Drug name stem: -arabine

Administration routes

Oral
Parenteral

Mechanism
DNA polymerase (alpha/delta/epsilon) inhibitor
Action type
Inhibitor
Target
DNA polymerase (alpha/delta/epsilon)
Protein identifier
P09884
Mechanism
DNA polymerase (alpha/delta/epsilon) inhibitor
Action type
Inhibitor
Target
DNA polymerase (alpha/delta/epsilon)
Protein identifier
P28340
Mechanism
DNA polymerase (alpha/delta/epsilon) inhibitor
Action type
Inhibitor
Target
DNA polymerase (alpha/delta/epsilon)
Protein identifier
P49005
Mechanism
DNA polymerase (alpha/delta/epsilon) inhibitor
Action type
Inhibitor
Target
DNA polymerase (alpha/delta/epsilon)
Protein identifier
P49642
Mechanism
DNA polymerase (alpha/delta/epsilon) inhibitor
Action type
Inhibitor
Target
DNA polymerase (alpha/delta/epsilon)
Protein identifier
P49643
Mechanism
DNA polymerase (alpha/delta/epsilon) inhibitor
Action type
Inhibitor
Target
DNA polymerase (alpha/delta/epsilon)
Protein identifier
P56282
Mechanism
DNA polymerase (alpha/delta/epsilon) inhibitor
Action type
Inhibitor
Target
DNA polymerase (alpha/delta/epsilon)
Protein identifier
Q07864
Mechanism
DNA polymerase (alpha/delta/epsilon) inhibitor
Action type
Inhibitor
Target
DNA polymerase (alpha/delta/epsilon)
Protein identifier
Q14181
Mechanism
DNA polymerase (alpha/delta/epsilon) inhibitor
Action type
Inhibitor
Target
DNA polymerase (alpha/delta/epsilon)
Protein identifier
Q15054
Mechanism
DNA polymerase (alpha/delta/epsilon) inhibitor
Action type
Inhibitor
Target
DNA polymerase (alpha/delta/epsilon)
Protein identifier
Q9HCU8
Mechanism
DNA polymerase (alpha/delta/epsilon) inhibitor
Action type
Inhibitor
Target
DNA polymerase (alpha/delta/epsilon)
Protein identifier
Q9NRF9
Mechanism
Ribonucleoside-diphosphate reductase RR1 inhibitor
Action type
Inhibitor
Target
Ribonucleoside-diphosphate reductase RR1
Protein identifier
P23921
Mechanism
Ribonucleoside-diphosphate reductase RR1 inhibitor
Action type
Inhibitor
Target
Ribonucleoside-diphosphate reductase RR1
Protein identifier
P31350
Mechanism
Ribonucleoside-diphosphate reductase RR1 inhibitor
Action type
Inhibitor
Target
Ribonucleoside-diphosphate reductase RR1
Protein identifier
Q7LG56

Mechanism
DNA polymerase (alpha/delta/epsilon) inhibitor
Action type
Inhibitor
Target
DNA polymerase (alpha/delta/epsilon)
Mechanism
Ribonucleoside-diphosphate reductase RR1 inhibitor
Action type
Inhibitor
Target
Ribonucleoside-diphosphate reductase RR1

Action type
Inhibitor
Gene symbol
POLA1
Protein identifier
P09884
Organism
Homo sapiens
Target development level
Clinical
Action type
Inhibitor
Gene symbol
RRM1
Protein identifier
P23921
Organism
Homo sapiens
Target development level
Clinical
Action type
Inhibitor
Gene symbol
RRM2
Protein identifier
P31350
Organism
Homo sapiens
Target development level
Clinical

Condition
Leukemia, Biphenotypic, Acute
Highest recorded phase
1
Condition identifier
EFO:0000094
Subject identifier
D015456
Condition
Leukemia, Lymphocytic, Chronic, B-Cell
Highest recorded phase
4
Condition identifier
EFO:0000095
Subject identifier
D015451
Condition
Lymphoma, Follicular
Highest recorded phase
3
Condition identifier
EFO:0000096
Subject identifier
D008224
Condition
Hodgkin Disease
Highest recorded phase
3
Condition identifier
EFO:0000183
Subject identifier
D006689
Condition
Lymphoma, B-Cell, Marginal Zone
Highest recorded phase
2
Condition identifier
EFO:0000191
Subject identifier
D018442
Condition
Prostatic Neoplasms
Highest recorded phase
1
Condition identifier
EFO:0000196
Subject identifier
D011471
Condition
Myelodysplastic Syndromes
Highest recorded phase
3
Condition identifier
EFO:0000198
Subject identifier
D009190
Condition
Neoplasms, Plasma Cell
Highest recorded phase
2
Condition identifier
EFO:0000200
Subject identifier
D054219
Condition
Lymphoma, T-Cell, Peripheral
Highest recorded phase
2
Condition identifier
EFO:0000211
Subject identifier
D016411
Condition
Leukemia, Erythroblastic, Acute
Highest recorded phase
3
Condition identifier
EFO:0000218
Subject identifier
D004915
Condition
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Highest recorded phase
3
Condition identifier
EFO:0000220
Subject identifier
D054198
Condition
Leukemia, Monocytic, Acute
Highest recorded phase
3
Condition identifier
EFO:0000221
Subject identifier
D007948
Condition
Leukemia, Myeloid, Acute
Highest recorded phase
3
Condition identifier
EFO:0000222
Subject identifier
D015470
Condition
Leukemia, Myelomonocytic, Acute
Highest recorded phase
3
Condition identifier
EFO:0000223
Subject identifier
D015479
Condition
Immunoblastic Lymphadenopathy
Highest recorded phase
2
Condition identifier
EFO:0000255
Subject identifier
D007119
Condition
Burkitt Lymphoma
Highest recorded phase
2
Condition identifier
EFO:0000309
Subject identifier
D002051
Condition
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Highest recorded phase
3
Condition identifier
EFO:0000339
Subject identifier
D015464
Condition
Crohn Disease
Highest recorded phase
2
Condition identifier
EFO:0000384
Subject identifier
D003424
Condition
Melanoma
Highest recorded phase
2
Condition identifier
EFO:0000389
Subject identifier
D008545
Condition
Lymphoma, Large B-Cell, Diffuse
Highest recorded phase
3
Condition identifier
EFO:0000403
Subject identifier
D016403
Condition
Leukemia
Highest recorded phase
3
Condition identifier
EFO:0000565
Subject identifier
D007938
Condition
Lymphoma
Highest recorded phase
3
Condition identifier
EFO:0000574
Subject identifier
D008223
Condition
Neoplasms
Highest recorded phase
4
Condition identifier
EFO:0000616
Subject identifier
D009369
Condition
Neuroblastoma
Highest recorded phase
2
Condition identifier
EFO:0000621
Subject identifier
D009447
Condition
Carcinoma, Renal Cell
Highest recorded phase
1
Condition identifier
EFO:0000681
Subject identifier
D002292

And 66 more, listed on the interactive page.

Condition identifier
EFO_0000095
Condition identifier
EFO_0000198
Condition identifier
EFO_0000220
Highest recorded phase
1
Condition identifier
EFO_0000222
Highest recorded phase
3
Condition identifier
EFO_0000389
Highest recorded phase
2
Condition identifier
EFO_0000403
Highest recorded phase
1
Condition identifier
EFO_0000565
Highest recorded phase
3
Condition identifier
EFO_0000574
Highest recorded phase
3
Condition identifier
EFO_0000616
Condition identifier
EFO_0000621
Highest recorded phase
2
Condition identifier
EFO_0000681
Condition identifier
EFO_0000717
Highest recorded phase
2
Condition identifier
EFO_0001378
Highest recorded phase
2
Condition identifier
EFO_0004251
Highest recorded phase
2
Condition identifier
EFO_0004281
Highest recorded phase
1
Condition identifier
EFO_0004289
Highest recorded phase
2
Condition identifier
EFO_0004952
Highest recorded phase
2
Condition identifier
EFO_0005952
Highest recorded phase
2
Condition identifier
EFO_0006859
Condition identifier
HP_0002863
Highest recorded phase
2
Condition identifier
HP_0005528
Highest recorded phase
2
Condition identifier
HP_0100727
Highest recorded phase
2
Condition identifier
MONDO_0000159
Highest recorded phase
2
Condition identifier
MONDO_0000159
Highest recorded phase
3
Condition identifier
MONDO_0000432
Highest recorded phase
3

And 81 more, listed on the interactive page.

Warning
Black Box Warning
Effect
hematological toxicity
Warning
Black Box Warning
Effect
neurotoxicity

Warning
Black Box Warning
Effect
hematological toxicity
Country
United States
Warning
Black Box Warning
Effect
neurotoxicity
Country
United States

Event
acute graft versus host disease
Reports
435
Reporting signal score
1,606.62
Event
acute graft versus host disease in intestine
Reports
114
Reporting signal score
425.331
Event
acute graft versus host disease in skin
Reports
295
Reporting signal score
1,151.95
Event
acute lymphocytic leukaemia recurrent
Reports
62
Reporting signal score
161.551
Event
acute myeloid leukaemia
Reports
164
Reporting signal score
323.838
Event
acute myeloid leukaemia recurrent
Reports
53
Reporting signal score
170.707
Event
adenovirus infection
Reports
204
Reporting signal score
738.208
Event
autoimmune haemolytic anaemia
Reports
121
Reporting signal score
315.719
Event
bacteraemia
Reports
146
Reporting signal score
247.626
Event
bk virus infection
Reports
135
Reporting signal score
372.716
Event
bone marrow failure
Reports
220
Reporting signal score
288.494
Event
bronchopulmonary aspergillosis
Reports
135
Reporting signal score
310.657
Event
chronic graft versus host disease
Reports
270
Reporting signal score
892.716
Event
chronic graft versus host disease in skin
Reports
48
Reporting signal score
143.774
Event
chronic lymphocytic leukaemia
Reports
74
Reporting signal score
157.074
Event
chronic lymphocytic leukaemia recurrent
Reports
199
Reporting signal score
884.97
Event
cystitis haemorrhagic
Reports
195
Reporting signal score
585.549
Event
cytokine release syndrome
Reports
494
Reporting signal score
1,537.35
Event
cytomegalovirus chorioretinitis
Reports
66
Reporting signal score
170.413
Event
cytomegalovirus infection
Reports
608
Reporting signal score
1,659.18
Event
cytomegalovirus infection reactivation
Reports
210
Reporting signal score
751.477
Event
cytomegalovirus viraemia
Reports
190
Reporting signal score
560.485
Event
cytopenia
Reports
119
Reporting signal score
192.352
Event
dizziness
Reports
64
Reporting signal score
150.468
Event
engraftment syndrome
Reports
66
Reporting signal score
255.404

And 34 more, listed on the interactive page.

NCT00001586
clinicaltrials.gov
NCT00003204
clinicaltrials.gov
NCT00009984
clinicaltrials.gov
NCT00060424
clinicaltrials.gov
NCT00079443
clinicaltrials.gov
NCT00086580
clinicaltrials.gov
NCT00090051
clinicaltrials.gov
NCT00098670
clinicaltrials.gov
NCT00119392
clinicaltrials.gov
NCT00220311
clinicaltrials.gov
NCT00275015
clinicaltrials.gov
NCT00276809
clinicaltrials.gov
NCT00281983
clinicaltrials.gov
NCT00391066
clinicaltrials.gov
NCT00565981
clinicaltrials.gov
NCT00602459
clinicaltrials.gov
NCT00612612
clinicaltrials.gov
NCT00727415
clinicaltrials.gov
NCT00794820
clinicaltrials.gov
NCT00801060
clinicaltrials.gov
NCT00845104
clinicaltrials.gov
NCT00868413
clinicaltrials.gov
NCT00918723
clinicaltrials.gov
NCT01145209
clinicaltrials.gov
NCT01529827
clinicaltrials.gov

And 204 more, listed on the interactive page.

Dose: 25 mg/m2
Route: Intravenous
How often: Once daily for five consecutive days every 4 weeks

Consider delaying or discontinuing if neurotoxicity occurs
Do not administer in severe renal impairment (creatinine clearance <30 mL/min/1.73 m2)
Dose reduction by 20% in moderate renal impairment
Monitor closely for toxicity in at-risk patients

Hydrogen bond acceptors: 10
Hydrogen bond donors: 5
Polar surface area: 186.07
Calculated partition coefficient (ALogP): -1.72
Calculated partition coefficient (XLogP): -3.1
Prodrug: Yes
Chirality: Single enantiomer
Inorganic: No
Rule-of-five violations: 0
Rotatable bonds: 4
Heavy atoms: 24
Molecular formula: C10H13FN5O7P
Monoisotopic mass: 365.05366293
Natural product: No

0527-1242
25021-242
42658-024
45963-609
59923-604
63323-192

Recorded assays: 410
Active assays: 40

Confirmatory
Other
Screening

Antimetabolites, Antineoplastic
id.nlm.nih.gov
Immunosuppressive Agents
id.nlm.nih.gov

Related records

Trials (1,627)

211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma
225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia
3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome
3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN
3RD GENERATION GD2 SPECIFIC CHIMERIC ANTIGEN RECEPTOR TRANSDUCED AUTOLOGOUS NATURAL KILLER T-CELLS FOR NEUROBLASTOMA
90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma
90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome
A 5 Day Course of Fludarabine and Cytarabine Followed by Full Intensity Allogeneic Stem Cell Transplantation (FA5-Bucy) in Treating Patients With High-risk, Recurrent or Refractory Acute Leukemia and Advanced Myelodysplastic Syndrome
A Clinical Research About CD70-targeted CAR-NKT Cells Therapy Advanced Malignant Solid Tumors
A Clinical Study to Evaluate the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Received Three or More Lines of Therapy
a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma Patients
A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors
A Clinical Trial to Assess the Efficacy and Safety of the Combination of a Drug Call Quizartinib With Chemotherapy (FLAG-IDA) in Patients With Acute Myeloid Leukemia That Has Not Responded to the First Treatment or That Has Returned After the First Treatment
A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC)
A Controlled Trial of Intermittent Fludarabine for Psoriatic Arthritis
A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malignancies
A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple Myeloma

Approved for (3)

In development for (86)

Acquired polycythemia vera Phase 2
Acute erythroid leukemia Phase 3
Acute leukemia of ambiguous lineage Phase 1
Acute lymphoblastic leukemia Phase 3
Acute megakaryoblastic leukemia Phase 3
Acute monocytic leukemia Phase 3
Acute myeloblastic leukemia without maturation Phase 3
Acute myeloid leukemia Phase 3
Acute myelomonocytic leukemia M4 Phase 3
Adult T-cell leukemia/lymphoma Phase 2
Anaplastic large cell lymphoma Phase 2
Angioimmunoblastic T-cell lymphoma Phase 2
Aplastic anemia Phase 3
B-cell acute lymphoblastic leukemia Phase 1
B-cell prolymphocytic leukemia Phase 2
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive Phase 1
Bone marrow failure syndrome Phase 3
Bone marrow neoplasm Phase 3
Breast cancer Phase 2
Breast neoplasm Phase 2

Targets (14)

POLA1 DNA polymerase (alpha/delta/epsilon) inhibitor
POLA2 DNA polymerase (alpha/delta/epsilon) inhibitor
POLD1 DNA polymerase (alpha/delta/epsilon) inhibitor
POLD2 DNA polymerase (alpha/delta/epsilon) inhibitor
POLD3 DNA polymerase (alpha/delta/epsilon) inhibitor
POLD4 DNA polymerase (alpha/delta/epsilon) inhibitor
POLE DNA polymerase (alpha/delta/epsilon) inhibitor
POLE2 DNA polymerase (alpha/delta/epsilon) inhibitor
POLE3 DNA polymerase (alpha/delta/epsilon) inhibitor
PRIM1 DNA polymerase (alpha/delta/epsilon) inhibitor
PRIM2 DNA polymerase (alpha/delta/epsilon) inhibitor
RRM1 Ribonucleoside-diphosphate reductase RR1 inhibitor
RRM2 Ribonucleoside-diphosphate reductase RR1 inhibitor
RRM2B Ribonucleoside-diphosphate reductase RR1 inhibitor

Fludarabine phosphate

Development status

Names and chemistry

Brand names (6)

Other names (38)

Identifiers

RxNorm IDs (RxCUI) (2)

Regulatory information

United States

Other regulatory facts

Pharmacology

Drug classification

Administration routes

Mechanisms of action (14)

Open Targets mechanisms (2)

DrugCentral mechanisms (3)

Investigated indications (91)

Open Targets indications (106)

Warnings (2)

Open Targets warnings (2)

Reported adverse events (59)

Trial references (229)

Dosing

Conditions of use (4)

Chemical properties

National Drug Codes

Evidence counts

Active assay types (3)

Pharmacologic actions

Related records

Trials (1,627)

Approved for (3)

In development for (86)

Targets (14)